Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders.
about
The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.Iron accumulation and neurotoxicity in cortical cultures treated with holotransferrinLeaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage.Increased Lysosomal Membrane Permeabilization in Oxidant-exposed Macrophages of Human Fibrotic Lungs.
P2860
Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@ast
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@en
type
label
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@ast
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@en
prefLabel
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@ast
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@en
P2860
P1476
Iron-binding drugs targeted to ...... t inflammatory lung disorders.
@en
P2093
Des R Richardson
H Lennart Persson
P2860
P304
P356
10.1517/13543784.14.8.997
P407
P577
2005-08-01T00:00:00Z